Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 8/20 | 0.57 |
| ▸ | SETDB1 | Q15047 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18091710 | 0.84 | DDR1 (0.50) | DDR1SETDB1ALDH1A1LMNAPOLB | |
| SCHEMBL15358174 | 0.81 | DDR1 (0.55) | DDR1ALDH1A1LMNAMAPK1POLB | |
| SCHEMBL16528580 | 0.79 | DDR1 (0.63) | DDR1ALDH1A1LMNAMAPK1POLB | |
| SCHEMBL3557506 | 0.77 | P2RX7 (0.53) | SETDB1ALDH1A1LMNAMAPK1NLRP1 | |
| SCHEMBL20196084 | 0.77 | DDR1 (0.88) | DDR1 | |
| SCHEMBL16529626 | 0.76 | DDR1 (0.54) | DDR1ALDH1A1LMNAMAPK1NLRP1 | |
| SCHEMBL3130070 | 0.76 | P2RX7 (0.56) | SETDB1ALDH1A1LMNAMAPK1NLRP1 | |
| SCHEMBL15358097 | 0.75 | DDR1 (0.84) | DDR1 | |
| SCHEMBL7109335 | 0.75 | KCNH2 (0.46) | SETDB1ALDH1A1LMNAMAPK1NLRP1 | |
| SCHEMBL20509926 | 0.74 | DDR1 (0.44) | DDR1SETDB1ALDH1A1LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2842939-B1 | BENZAMIDE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-9695118-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2017-07-04 | — | — | US | disclosed |
| US-20150152047-A1 | BENZAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2842939-A1 | BENZAMIDE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2015-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152047-A1 | BENZAMIDE DERIVATIVE | CYP3A5, HDAC6, BRD1 | DDR1 4353/4885SETDB1 1453/4885ALDH1A1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.